Business Model Breakdown
How Gilead Sciences Inc Makes Money
GILD
Market Cap
$159.9B
Annual Revenue
$30.1B
Profit Margin
28.9%
Employees
17,600
The Short Version
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines globally. Historically, its primary revenue sources have been its market-leading treatments for HIV and hepatitis. In recent years, it has strategically expanded into oncology, particularly in advanced cell therapies and antibody-drug conjugates, through significant acquisitions to diversify its product portfolio. The company generates revenue by selling its patented drugs to healthcare providers, hospitals, and government programs worldwide, relying on its strong research and development capabilities, intellectual property protection, and global commercial infrastructure to deliver high-value therapeutics to patients.
Where the Revenue Comes From
HIV Products (~50-60% of revenue, primarily Biktarvy)
Oncology Products (~15-20% of revenue, growing rapidly via acquisitions like Trodelvy, Yescarta, Arcellx, Tubulis)
Hepatitis Products (~5-10% of revenue)
Who buys: Healthcare providers, hospitals, pharmacies, government entities, and managed care organizations.
Why It Works (Competitive Advantages)
- ✔Dominant intellectual property and market share in HIV treatments (Biktarvy)
- ✔Strong cash flow generation from mature assets funding oncology pivot
- ✔Emerging platforms in cell therapy (CAR T) and Antibody-Drug Conjugates (ADCs) through recent acquisitions
- ✔Global commercial infrastructure and regulatory expertise
Economic Moat: Narrow (Intangible Assets/IP, Switching Costs)
What Our Analysis Says
DVR Score as of April 30, 2026
Gilead Sciences remains a financially robust biopharmaceutical giant, excelling in HIV treatment and rapidly expanding its oncology footprint through aggressive M&A. While its core business generates substantial cash flow and its strategic pivot via recent multi-billion dollar acquisitions (Arcellx, Tubulis) is a strong positive signal for future growth and diversification, these moves are geared towards sustained, significant growth rather than exponential 10x potential for a company of its $160B scale within 3-5 years. The near-term EPS dilution from these acquisitions underscores the long investment horizon required. While the strategy for future market leadership in specific oncology niches is compelling, the path to a $1.6 trillion valuation remains highly improbable.